Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

Figure 7

Correlation of risk signature with tumor-infiltrating immune cells in TCGA and ICGC HCC cohort. Difference of 22 kinds of infiltrating immune cells between patients with different risk scores of (a) TCGA HCC cohort. Difference of 22 kinds of infiltrating immune cells between patients with different risk scores of (b) ICGC HCC cohort.

(a)

(b)